CLSD Stock Price, Clearside Biomedical Inc Quote, Chart

Market Summary

USD1.310.00

Market Closed

0.00%

CLSD Alerts

1 major insider buys recently.

CLSD Stock Price

View Fullscreen

CLSD RSI Chart

CLSD Valuation

Market Cap

97.9M

Price/Earnings (Trailing)

-2.8

Price/Sales (Trailing)

11.9

Price/Free Cashflow

-4.78

CLSD Price/Sales (Trailing)

CLSD Profitability

Return on Equity

160.33%

Return on Assets

-87.11%

Free Cashflow Yield

-20.93%

CLSD Fundamentals

CLSD Revenue

Revenue (TTM)

8.2M

Rev. Growth (Yr)

1.8K%

Rev. Growth (Qtr)

638.65%

CLSD Earnings

Earnings (TTM)

-35.0M

Earnings Growth (Yr)

-26.76%

Earnings Growth (Qtr)

-143.44%

Breaking Down CLSD Revenue

Last 7 days

4.8%

Last 30 days

4.0%

Last 90 days

4.8%

Trailing 12 Months

29.7%

How does CLSD drawdown profile look like?

CLSD Financial Health

Current Ratio

6.07

Debt/Equity

-0.02

Debt/Cashflow

-48.75

CLSD Investor Care

Shares Dilution (1Y)

21.19%

Diluted EPS (TTM)

-0.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	3.1M	4.8M	6.5M	8.2M
2022	22.5M	15.5M	8.4M	1.3M
2021	13.3M	18.7M	24.2M	29.6M
2020	6.2M	6.5M	9.8M	7.9M
2019	565.8K	1.1M	1.6M	2.2M
2018	0	0	0	30.0K
2017	476.3K	432.5K	388.8K	345.0K
2016	0	0	0	520.0K
2015	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Clearside Biomedical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	gibney anthony s	bought	121,277	1.3	93,290	-
Apr 17, 2024	gibney anthony s	bought	8,387	1.25	6,710	-
Mar 20, 2024	chong ngai hang victor	bought	48,000	1.6	30,000	chief medical officer
Feb 07, 2024	whitmore bradford t	bought	599,999	1.35	444,444	-
Jan 19, 2024	deignan charles a.	sold	-16,512	1.28	-12,900	chief financial officer
Jan 19, 2024	lasezkay george m	sold	-22,860	1.27	-18,000	ceo
Nov 01, 2023	whitmore bradford t	bought	47,901	0.7442	64,366	-
Oct 31, 2023	whitmore bradford t	bought	51,537	0.7278	70,812	-
Oct 30, 2023	whitmore bradford t	bought	411	0.685	600	-
Oct 03, 2023	hutson nancy j	bought	8,600	0.86	10,000	-

Which funds bought or sold CLSD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	270,360	270,360	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	104,749	104,749	-%
May 15, 2024	FIRST MANHATTAN CO. LLC.	unchanged	-	63,000	267,750	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	401	7,324	8,641	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	sold off	-100	-12,870	-	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	37,592	37,592	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	6,052,680	6,052,680	0.08%
May 15, 2024	Northeast Financial Consultants Inc	unchanged	-	33,480	142,290	0.01%
May 15, 2024	Mariner, LLC	unchanged	-	6,822	28,994	-%
May 15, 2024	Curi RMB Capital, LLC	new	-	38,250	38,250	-%

Are Funds Buying or Selling CLSD?

Are funds buying CLSD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLSD

No. of Funds

CLSD Alerts

1 major insider buys recently.

Unveiling Clearside Biomedical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 01, 2023	whitmore bradford t	10.1%	6,264,964	SC 13G/A
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 13, 2023	carmignac gestion	3.98%	2,400,344	SC 13G/A
Jan 04, 2023	hatteras venture advisors iii, llc	0%	0	SC 13D/A
Jan 04, 2023	whitmore bradford t	9.9%	6,017,852	SC 13G/A
Feb 14, 2022	rtw investments, lp	6.4%	3,806,018	SC 13G/A
Feb 09, 2022	carmignac gestion	5.2%	3,124,252	SC 13G/A
Jan 24, 2022	whitmore bradford t	9.9%	5,878,197	SC 13G/A
Feb 12, 2021	rtw investments, lp	8.19%	3,958,130	SC 13G/A
Feb 12, 2021	carmignac gestion	7.3%	3,540,961	SC 13G

Recent SEC filings of Clearside Biomedical Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	4	Insider Trading
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	S-8	Employee Benefits Plan
May 09, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 19, 2024	4	Insider Trading
Apr 16, 2024	3	Insider Trading
Apr 16, 2024	4	Insider Trading

Peers (Alternatives to Clearside Biomedical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Clearside Biomedical Inc News

Latest updates

Clearside Biomedical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	6,345	859	1,018	674	330	266	384	13,036	25,687	3,074	780	396	11.00	3,432	354	4,097	1,942	141	45.00	45.00
Operating Expenses	-8.9%	8,439	9,260	7,913	8,288	7,609	8,400	6,990	8,221	7,993	6,980	7,963	6,876	8,383	7,121	5,864	5,911	6,933	4,955	6,509	5,662	15,351
S&GA Expenses	-100.0%	-	2,947	2,637	3,127	3,158	3,169	2,353	2,791	3,457	3,140	2,816	2,816	2,893	2,649	2,374	2,611	3,122	3,650	3,781	5,004	4,384
R&D Expenses	-11.1%	5,615	6,313	5,134	4,948	4,451	5,027	4,637	5,430	4,536	3,840	5,147	4,060	5,490	4,472	3,490	3,300	3,811	1,305	2,728	658	10,967
Net Income	-143.4%	-11,763	-4,832	-9,267	-9,106	-9,280	-9,663	-7,827	-7,813	-7,644	18,709	-4,887	-6,095	-7,351	-7,112	-2,433	-5,754	-2,911	-3,096	-6,536	-5,734	-15,404
Net Income Margin	-7.6%	-4.25*	-3.95*	-5.74*	-7.51*	-11.33*	-24.83*	-0.55*	-0.11*	0.00*	0.01*	-1.05*	-1.23*	-	-	-	-	-	-	-	-	-
Free Cashflow	-2208.8%	-7,908	375	-6,520	-6,436	-7,331	-5,698	-6,341	-5,443	3,871	5,054	-3,278	-6,950	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	18.0%	40.00	34.00	34.00	39.00	45.00	51.00	56.00	31.00	36.00	43.00	27.00	29.00	28.00	19.00	17.00	18.00	25.00	27.00	26.00	30.00	38.00
Current Assets	19.9%	36.00	30.00	31.00	36.00	43.00	49.00	55.00	30.00	35.00	42.00	27.00	28.00	27.00	18.00	16.00	16.00	24.00	25.00	24.00	28.00	35.00
Cash Equivalents	22.4%	35.00	29.00	29.00	35.00	41.00	48.00	53.00	29.00	34.00	30.00	25.00	26.00	26.00	17.00	15.00	15.00	21.00	23.00	23.00	26.00	33.00
Net PPE	6.6%	3.00	3.00	3.00	2.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	24.1%	62.00	50.00	47.00	44.00	42.00	41.00	37.00	5.00	4.00	5.00	10.00	9.00	11.00	11.00	9.00	10.00	15.00	16.00	16.00	17.00	21.00
Current Liabilities	-12.7%	6.00	7.00	6.00	5.00	5.00	6.00	5.00	5.00	4.00	5.00	9.00	9.00	10.00	10.00	8.00	9.00	14.00	11.00	11.00	8.00	12.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	-	4.00	4.00	8.00	9.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	0.00	5.00	1.00	6.00	2.00	1.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	-	4.00	4.00	8.00	9.00
Shareholder's Equity	-37.1%	-21.81	-15.91	-	-	3.00	11.00	19.00	25.00	32.00	38.00	18.00	19.00	17.00	9.00	8.00	7.00	10.00	11.00	10.00	13.00	16.00
Retained Earnings	-3.7%	-332	-320	-316	-306	-297	-288	-278	-270	-263	-255	-274	-269	-263	-255	-248	-246	-240	-237	-234	-228	-222
Additional Paid-In Capital	1.9%	311	305	303	302	300	299	297	296	295	293	292	289	280	265	257	254	251	249	244	241	238
Shares Outstanding	18.9%	75.00	63.00	62.00	62.00	61.00	61.00	60.00	60.00	60.00	58.00	59.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	64.00	-	-	-	80.00	-	-	-	228	-	-	-	66.00	-	-	-	33.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-1686.1%	-7,851	495	-6,075	-5,339	-7,216	-5,607	-6,186	-5,443	3,871	5,054	-3,278	-6,950	-5,559	-4,436	-2,661	-3,220	-2,803	1,689	-6,047	-10,057	-12,653
Share Based Compensation	3.5%	1,062	1,026	1,074	1,061	1,041	1,149	1,074	1,354	1,307	1,253	1,316	1,331	1,154	867	841	891	1,001	1,139	970	1,256	1,247
Cashflow From Investing	52.5%	-57.00	-120	-445	-1,097	-115	-91.00	-155	-	-	-	-	-	-	-	-110	110	-55.00	-	-	1,993	30,932
Cashflow From Financing	5680.9%	14,343	-257	317	22.00	332	575	30,689	4.00	65.00	165	2,081	7,117	14,419	6,884	-463	253	1,193	-1,645	2,424	1,288	6,628

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLSD Income Statement

2024-03-31

Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
License and other revenue (includes $75 from a related party for the three months ended March 31, 2024)	$ 230	$ 4
Type of Revenue [Extensible List]	us-gaap:LicenseMember	us-gaap:LicenseMember
Operating expenses:
Research and development (includes $256 to a related party for the three months ended March 31, 2024)	$ 5,615	$ 4,451
General and administrative	2,824	3,158
Total operating expenses	8,439	7,609
Loss from operations	(8,209)	(7,605)
Interest income	348	492
Other expense	(1,499)	0
Non-cash interest expense on liability related to the sales of future royalties	(2,403)	(2,167)
Net loss	$ (11,763)	$ (9,280)
Net loss per share of common stock - basic	$ (0.17)	$ (0.15)
Net loss per share of common stock - diluted	$ (0.17)	$ (0.15)
Weighted average shares outstanding - basic	69,853,227	61,169,486
Weighted average shares outstanding - diluted	69,853,227	61,169,486

CLSD Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,355	$ 28,920
Accounts receivable	0	170
Prepaid expenses	567	722
Other current assets	193	311
Total current assets	36,115	30,123
Property and equipment, net	3,194	2,996
Operating lease right-of-use asset	803	869
Other assets	30	30
Total assets	40,142	34,018
Current liabilities:
Accounts payable (includes $17 and $331 to a related party as of March 31, 2024 and December 31, 2023, respectively)	1,363	2,205
Accrued liabilities (includes $198 and $215 to a related party as of March 31, 2024 and December 31, 2023, respectively)	4,070	4,169
Current portion of operating lease liabilities	367	364
Deferred revenue	150	75
Total current liabilities	5,950	6,813
Liability related to the sales of future royalties, net	44,391	41,988
Warrant liabilities	11,039	0
Operating lease liabilities	572	649
Other non-current liabilities	0	480
Total liabilities	61,952	49,930
Commitments and contingencies
Stockholders' (deficit) equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 74,731,139 and 62,850,841 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	74	63
Additional paid-in capital	310,802	304,948
Accumulated deficit	(332,686)	(320,923)
Total stockholders' (deficit) equity	(21,810)	(15,912)
Total liabilities and stockholders' (deficit) equity	$ 40,142	$ 34,018

About Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CEO	Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
WEBSITE	https://clearsidebio.com
INDUSTRY	Biotechnology
EMPLOYEES	36

Clearside Biomedical Inc Frequently Asked Questions

What is the ticker symbol for Clearside Biomedical Inc? What does CLSD stand for in stocks?

CLSD is the stock ticker symbol of Clearside Biomedical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clearside Biomedical Inc (CLSD)?

As of Fri May 17 2024, market cap of Clearside Biomedical Inc is 97.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLSD stock?

You can check CLSD's fair value in chart for subscribers.

What is the fair value of CLSD stock?

You can check CLSD's fair value in chart for subscribers. The fair value of Clearside Biomedical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Clearside Biomedical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLSD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Clearside Biomedical Inc a good stock to buy?

The fair value guage provides a quick view whether CLSD is over valued or under valued. Whether Clearside Biomedical Inc is cheap or expensive depends on the assumptions which impact Clearside Biomedical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLSD.

What is Clearside Biomedical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CLSD's PE ratio (Price to Earnings) is -2.8 and Price to Sales (PS) ratio is 11.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLSD PE ratio will change depending on the future growth rate expectations of investors.